The 2026 Nobel Prizes for Medicine, Physics, and Chemistry were announced this week. These prizes recognize breakthroughs in optogenetics, the astronomy of neutrinos, and asymmetric autocatalysis. These discoveries are already beginning to transform medicine, astronomical research, and the manufacture of drugs.
Medicine: From “Seeing the Brain” to “Treating the Brain”
This year’s Nobel prize in medicine or physiology was awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for their development of optogenetics, a method by which individual nerve cells in the living brain can be controlled by light.
For two decades now, this method has been used to put a light on or off neural circuits with incredible precision, and has given us a glimpse into the neural basis of memory, emotions, and behavior. But now, the biggest changes are coming from the laboratory to the clinic.
In the near future, vision restoration appears the most likely use of the new technology. An international group of investigators led by José Alain Sahel of the University of Pittsburgh and Botond Roska of the Basel Institute for Molecular and Clinical Ophthalmology has just published the results of clinical trials of optogenetic therapy for patients with late-stage retinitis pigmentosa. * This study was carried out in association with GenSight Biologics and was published in the New England Journal of Medicine.
Each participant received a single injection of the genetic code of ChrimsonR, a light-sensitive protein, into the eye of his weaker eye. They used special eyeglasses, which transformed the visual scenes of the world into pulsations of amber light.
Result: Of the ten patients studied, seven had a more sensitive sensitivity to light, with an increase ranging from a factor of 2.0 to 62.3. Six had reached the required threshold for clinically significant improvement. Four of eight patients who underwent tests on visual behaviour showed an improvement.
The treatment did not restore normal vision; the patient could still not see faces and could not read. But the experiment proved that, even in a state of almost complete blindness, retinal ganglion cells, if stimulated by light, could respond to visual information and send it to the brain.
Human brain optogenetics is still subject to some obstacles, mainly relating to the safety and long-term stability of gene expression. Trials on the eye are proceeding, but brain surgery is still some time off, possibly years or even decades. But the trials on the eyes are progressing, while the brain operation is still a long way off, probably years.
Physics: From “Seeing the Universe” to “Seeing It More Clearly”
The prize for physics was awarded to Francis Halzen from the University of Wisconsin-Madison for the ice cube neutrino observatory for the discovery of cosmic high-energy neutrinos.
Neutrinos are the most elusive messengers in the universe; they have no electrical charge, and are so weakly affected by matter that most of them go straight through the earth without leaving a trace. But this also means that they travel in straight lines from the most violent cosmic events, conveying information which light cannot carry…
IceCube was constructed of a cubic kilometre of polar ice and was equipped with more than 5,000 photomultipliers buried between 1,450 and 2,450 metres below the surface. When a rare neutrino encounters an atomic nucleus, it produces a faint flash of blue light which is detected by the sensors.
In 2013, the IceCube neutrino observatory provided the first compelling evidence of high-energy neutrinos arriving from deep space. In 2018, a high-energy neutrino was traced back to a blazar (a jet-emitting supermassive black hole) some 3.7 billion light-years away. This discovery opened up a new field of astronomy.
From tomorrow, the improved IceCube is going to start making even more accurate observations. A major overhaul in February 2026 gave it over 600 new sensors, each with twenty-four photomultipliers arranged in all directions, and lowered the detection threshold so as to detect many more atmospheric events.
A much larger project, called IceCube-Gen2, is currently under consideration and awaiting funding approval. It would further increase the sensitivity of the experiment and raise the volume of the ice tenfold, to approximately 8 cubic kilometers. This may help solve the problem of whether the mass of the third [neutrino is heavier or lighter than the other two][6].
Chemistry: From “Understanding Chirality” to “Making Cheaper Drugs”
The prize in chemistry went to Henri Kagan (www.icmorb.u-psud.fr) and Kenso Soai (www.tmu.ac.jp) for the discovery of nonlinear phenomena and autocatalysis in asymmetric synthesis.
CHEMICAL CHIRALITY is the property of molecules that are “left-handed” and “right-handed”, which are identical as to composition but inverse in shape like the right hand and left hand which cannot be superimposed on each other. Moreover, it is precisely this property that life finds extremely interesting: most medicinal substances are only effective in one of these configurations, the other is usually ineffective or even harmful.
It was a problem of how to efficiently manufacture the correct-handed product. The traditional approach was to make a mixture of both molecules and then separate them, which inevitably wasted at least half of the starting materials. Asymmetric synthesis could help bias the reaction towards the desired molecule, but some catalysts are expensive and require extreme conditions.
In 1986 Kagan’s discovery of a nonlinear effect[8] in asymmetric catalysis, which broke the then firmly established idea that the enantiomeric excess of a product relates linearly to the optical purity of the chiral ligand, was the first to report an asymmetry in the optical activity of the product higher than that of the chiral ligand.
Soai is credited with having invented the first chemical reaction that only produces one of the potential mirror images. His asymmetric self-propagation of enantiomeric excess amplification reaction (a.k.a. the Soai reaction) demonstrates that a tiny initial disparity can be amplified to an enantiomeric excess of over 99.5% in three successive reactions.
The chemistry committee noted that if these principles can be transferred to industrial practice, the cost of producing chiral drugs could be reduced considerably. The Nobel Committee also said that Kagan’s discovery has been revolutionary for chemists developing reactions for making pharmaceuticals, flavours, scents and new materials.
Nevertheless, care must be taken. It has not yet been applied to industrial production. The path from the laboratory to the factory still needs a lot of exploration.
The real impact of a prize is not felt on the day of its announcement. It emerges slowly over a decade or two, changing the way we treat disease, observe the universe and manufacture medicine. Three prizes, three rhythms of change: optogenetics has been tested in the eye; the application to the brain will take longer. The astro-neutrino telescope has already been installed in the ice of Antarctica; it will emerge in the years to come; the chiral catalysis is a longer translation cycle.
SARAH CLARK